Tranzyme Pharma

Tranzyme became a publicly traded company on April 1, 2011.

Tranzyme shares trade on the NASDAQ Global Market under the symbol "TZYM".

Tranzyme offered 13,500,000 shares of its common stock to the public at a price of $4.00 per share.

Tranzyme maintains operations in both the U.S. and Canada. The Company's headquarters and center for business development, clinical development and regulatory activities are in Durham, North Carolina. The Company's medicinal chemistry, lead optimization and preclinical development activities are based in Quebec, Canada.

Tranzyme does not offer a direct stock purchase program.

The Company's fiscal year ends on December 31.

Tranzyme's SEC filings are listed under the Financial Information tab in the Investor Relations section of the Tranzyme website.

No. Tranzyme does not anticipate paying any dividends on its capital stock in the foreseeable future.

Tranzyme's transfer agent can be contacted in writing, by phone or via email at:

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
212.509.4000x206
cstmail@continentalstock.com

Click here to contact investor relations.

Please submit your question using the form below. * Required fields

Name *
Email *
Subject *
Comments *
Type in number *
	This helps Tranzyme Pharma prevent automated submissions.